Infectious Diseases and Clinical Pharmacology
Professor of Clinical Pharmacy
Director of Experiential Education in Los Angeles- Orange County
Skaggs School of Pharmacy and Pharmaceutical Sciences
Pediatric Infectious Diseases and Clinical Pharmacology
Dr. Jennifer Le is Professor of Clinical Pharmacy at the University of California, San Diego Skaggs School of Pharmacy and Pharmaceutical Sciences. She received her Bachelors of Science in Biology from University of California, Los Angeles in 1995; PharmD from University of California, San Francisco in 2000; and Masters in Clinical Research from University of California, San Diego in 2012. As a board-certified pharmacotherapy specialist with added qualification in infectious diseases since 2007, Dr. Le has been involved in clinical pharmacy services in pediatric infectious diseases and patient-oriented research over 19 years. She is an invited member of the federal advisory board for the Food and Drug Administration’s (FDA) Antimicrobial Drugs Advisory Committee that makes official recommendations to FDA about safety and efficacy of antibiotics for use in the United States. She is also a member of Healthcare Patient Safety and Quality Improvement Research Study Section for the Agency for Healthcare Research and Quality (AHRQ); expert panel member for Pediatric ECMO Anticoagulation. CollaborativE (PEACE) Consensus Guidelines; an advisory board member of the Asian Pacific Health Foundation; has also been a member of an NIH Special Emphasis Panel and participates in Scientific Review Groups; is an invited editorial board member for Pediatric Pharmacotherapy, Pharmacotherapy Journal, Pediatric Medicine and Infectious Diseases and Therapy Journal; and invited program reviewer for the national board certification programs through the American College of Clinical Pharmacy, including Self-Assessment Programs in Pediatrics (PedSAP), Ambulatory Care (ACSAP), and Pharmacotherapy (PSAP).
Dr. Le’s primary research encompasses three domains: (1) the appropriate and safe use of antibiotics and antifungal agents, (2) clinical pharmacology, and (3) outcomes associated with resistant infections in pediatrics across the wide age spectrum from infancy (including critically-ill premature neonates) to adolescence. She specializes in pharmacokinetics – the processes by which a drug is absorbed, distributed, metabolized and eliminated by the body – and pediatric clinical pharmacology research. She has published over 135 articles in reputable medical and pharmacy journals and books, including Pediatrics, Journal of Pediatrics, and Merck Manuals and serves as the second author of the current vancomycin guidelines endorsed by the American Society of Health-System Pharmacists, Infectious Diseases Society of America, Pediatric Infectious Diseases Society and Society of Infectious Diseases Pharmacists. Dr. Le was a past recipient of the American College of Clinical Pharmacy’s Investigator Development Award and the K23 Career Development Award from the National Institutes of Health for her research in pharmacokinetic-pharmacodynamic modeling of antibiotics in children. She also serves as an investigator for pharmacokinetic studies through the RO1, U54 & T32/34 award mechanisms for developmental and translational pharmacology of pediatric antimicrobial therapy funded by the National Institutes of Health. She was bestowed the honor of fellow of the Infectious Diseases Society of America, American College of Clinical Pharmacy and California Society of Health Systems Pharmacists; and received awards such as Sternfels Prize for Drug Safety Innovation and Outstanding Mentor at University of California, San Diego Faculty Mentor Program. Dr. Le is most proud of her passion and continued effort to improve pediatric health and wellness extending globally through her humanitarian work in Vietnam, Taiwan and for Jordan over the past 10 years.
Education: B.S. in Biology (1995) UCLA; Pharm.D. (2000) UCSF; ASHP-accredited Residency in Pharmacy Practice (2001) Long Beach Memorial and Miller Children's Hospital; Board certification in pharmaceutical sciences with added qualification in infectious diseases (2007 & 2014) (BCPS-ID); APhA-certified in pharmacy-based immunization delivery (2008); MAS in Clinical Research (2012).
Awards and Honors: RO1 Award from NICHD (2018-2022); Pediatric Trials Network Antibiotic Safety in Infants with Complicated Intra-abdominal Infections (2018-2019); Sternfels Prize for Drug Safety Innovation (2018); U54 Specialized Centers in Research in Pediatric Developmental Pharmacology from NICHD (2016-2021); K23 Award from NIAID (2010- 2015); New Investigator Award from ACCP (2007); Faculty Service of the Year Award at Western Univ. (2009); Rho Chi Honor Society Member; Fellow of ACCP (2011); Fellow of CSHP (2013); Fellow of Infectious Diseases Society of America (2017); Faculty Mentorship Training Program at UC San Diego Health Sciences (2018); Faculty Leadership Academy at UC San Diego Health Sciences (2019)
Leadership Experience: Editorial board member for Pharmacotherapy, Pediatric Pharmacotherapy and Infectious Diseases and Therapy Journal and Pediatric Medicine; Journal/book reviewer for Clinical Infectious Diseases, Pediatr Infect Dis J, J of Antimicrob Chemother, Clin Therapeutics and PSAP Infectious Diseases; Faculty Panel Chair for PedSAP; Advisory Board Member of Antimicrobial Drugs Advisory Committee for United States Food and Drug Administration; Advisory Board Member for Asian Pacific Health Foundation
- Intro to Clinical Pharmacokinetics and Special Populations including Pediatrics, Geriatrics and Obesity (SPPS 212A)
- Digoxin and Anticonvulsants Pharmacokinetics (SPPS 212B & 212C)
- Pediatric Infections (SPPS 212D)
- Pneumonia and Viral Infections (SPPS 212D)
- Clinical Pharmacokinetics of Vancomycin and Aminoglycosides (SPPS 212D)
- Co-Chair of Infectious Disease Therapeutics Course (SPPS 212D)
- Acute Care Advanced Pharmacy Practice Experiences
- Lecturer for University Medical Center Ho-Chi Minh City, Vietnam; Chinese Medical University, Taiwan and Hospital for Tropical Diseases, Vietnam
- Pharmacokinetic-pharmacodynamic modeling and Monte Carlo simulations of antimicrobial agents in pediatrics.
- Effective use of antimicrobial medications in pediatric and adult hospitalized patients.
- Clinical research in antimicrobial medication utilization in the inpatient setting.
- Le et al. (2015) Bayesian estimation of vancomycin pharmacokinetics in obese children: matched case-control study. Clinical Therapeutics. 37:1340-51.
- Le et al. (2017-19) Pharmacokinetics of single-dose ceftaroline fosamil in children with cystic fibrosis. Pediatric Pulmonology. 11:1424-1434
- Le (2017). Pharmacokinetics. In: The Merck Manual of Diagnosis and Therapy. Whitehouse Station, NJ: Merck Sharp & Dohme Corp. Prof. & Consumer versions. Website: www.merckmanuals.com
- Le (2017). Upper respiratory tract infections and Kawasaki disease. In: Pediatric Pharmacotherapy. Editors: Nahata M, Lenexa, Kansas: American College of Clinical Pharmacy.
- Le et al. (2017) Pharmacokinetic alterations in obese children. Podcast by ACCP Part 1: https://itunes.apple.com/us/podcast/episode-7-part-1/id1175416904?i=1000383843377&mt=2 and Part 2: https://itunes.apple.com/us/podcast/episode-7-part- 2/id1175416904?i=1000383843378&mt=2
- Le J et al. (2018). Optimizing Antibiotic Drug Therapy in Pediatrics: Current State and Future Needs. J Clin Pharmacol 2018;58 Suppl 10:S108-S122.
- Le J et al (2018). Comparative Analysis of Ampicillin Plasma and Dried Blood Spot Pharmacokinetics in Neonates. Ther Drug Monit 2018; 40:103-108.
- Jimenez A, Tran TM, Le B and Le J (2020). Comparative Cross-Sectional Pharmacovigilance Study of Medication Errors in Children and Adults in Community-Based Hospitals. J Pediatrics Child Health 2020;2:1-12.
- Avedissian SN, Rhodes NJ, Kim Y, Bradley J, Valdez JL, and Le J (2020). Augmented renal clearance of aminoglycosides using population-based pharmacokinetic modelling with Bayesian estimation in the paediatric ICU. J Antimicrob Chemother. 2020;75:162-169.
- Rybak MJ, Le J, et al (2020). Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: A revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 2020;77:835-864.
- Identify opportunities for research programs surrounding optimal antimicrobial use and dosing in patients, especially children, with resistant infections
- Develop service interventions and novel practice models that will improve utilization of antimicrobial medications in hospitalized pediatric and adult patients
- Conduct pharmacokinetic-pharmacodynamic modeling of antimicrobial agents in pediatrics